Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)

doi:10.21037/apm-21-2828

	Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)
	Si, Jinfei 1,2,3; Gu, Xiaodong 1,2,3; Wang, Wenxian 1,3; Ying, Shenpeng 4; Song, Zhengbo 1,3
刊名	ANNALS OF PALLIATIVE MEDICINE
	2021-12-16
关键词	Epidermal growth factor receptor (EGFR) uncommon mutation compound mutation double uncommon mutation lung adenocarcinoma (lung AC)
ISSN号	2224-5820
DOI	10.21037/apm-21-2828
通讯作者	Song, Zhengbo(songzb@zjcc.org.cn)
英文摘要	Background: This study aimed to explore the efficacy of different epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (AC) patients harboring uncommon EGFR mutations. Methods: Between January 1st, 2013 and October 1st, 2019, 2,680 EGFR mutation-positive patients with confirmed stage IIIB/IV lung AC were enrolled from Zhejiang Cancer Hospital. Uncommon EGFR mutations were detected in 132 patients using next-generation-sequencing. Clinicopathological features between patients with uncommon EGFR mutations and common EGFR mutations were evaluated by the chi-square test. The clinical outcomes of patients with uncommon EGFR mutations were analyzed by the Kaplan-Meier method. Results: Of 132 AC patients with uncommon EGFR mutations, 115 received EGFR-TKIs. Second-generation EGFR-TKIs were associated with longer progression-free survival (PFS) (P=0.116) and overall survival (OS) (P=0.005) than first or third-generation EGFR-TKIs. We also found that patients with compound mutations and double uncommon EGFR mutations had longer PFS (P=0.725) and OS (P=0.741) than those with single uncommon EGFR mutation, although the difference was not significant. In addition, third-generation EGFR-TKIs were more effective than the other two agents in patients with primary T790M, mutation regarding PFS (P=0.150) and OS (P=0.033), although the difference in PFS was not significant. Conclusions: Patients with uncommon EGFR mutations treated with second-generation EGFR-TKIs showed better PFS and OS. EGFR-TKIs were more effective in patients with compound mutations or double uncommon mutations.
资助项目	Fund of the Science and Technology Department of Taizhou City[1801ky36]
WOS关键词	NSCLC PATIENTS ; CANCER NSCLC ; AFATINIB ; OSIMERTINIB ; RESISTANCE ; GEFITINIB
WOS研究方向	Health Care Sciences & Services
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000739876000001
资助机构	Fund of the Science and Technology Department of Taizhou City
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/127219]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo
作者单位	1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Clin Trial, 1 Banshan East Rd, Hangzhou 310022, Peoples R China 4.Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Radiotherapy, Taizhou, Peoples R China
推荐引用方式 GB/T 7714	Si, Jinfei,Gu, Xiaodong,Wang, Wenxian,et al. Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)[J]. ANNALS OF PALLIATIVE MEDICINE,2021.
APA	Si, Jinfei,Gu, Xiaodong,Wang, Wenxian,Ying, Shenpeng,&Song, Zhengbo.(2021).Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs).ANNALS OF PALLIATIVE MEDICINE.
MLA	Si, Jinfei,et al."Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)".ANNALS OF PALLIATIVE MEDICINE (2021).